Ipsos Healthcare Launches ‘NASH’ Therapy Monitor
Ipsos Healthcare has launched its Nonalcoholic Steatohepatitis (NASH) Therapy Monitor in the US and EU5 initially – France, Germany, Italy, Spain, and UK – with other markets available on demand.
This development comes in response to the growing focus on Nonalcoholic Steatohepatitis (NASH) – a liver disease characterised by rising prevalence, low diagnosis levels and a lack of therapies currently approved for treatment.
The new NASH patient chart audit – part of Ipsos’ Global Therapy Monitor Portfolio – will allow subscribers to understand and track the treatment of NASH as a number of pipeline drugs arrive on the market. Ipsos will leverage the knowledge of its Virology & Liver Diseases Centre of Excellence (CoE) together with the proven formula of Global Therapy Monitors to answer a multitude of questions about this increasingly important disease.
Dr Sabina Heinz, who heads up the NASH Therapy Monitor, commented:
Given its rising prevalence, low diagnosis and lack of approved therapies, NASH is a growing priority for the healthcare industry – and, potentially, a multi-billion-dollar market. The NASH Therapy Monitor will give us deeper insight into the current patient populations and barriers to diagnosis, as well as providing input into forecasts on the potential uptake of new therapies once launched.
